Interstitial laser coagulation (ILC) treatment is a recent technique in the treatment of BPH that is evolving rapidly. The results of a prospective randomised study vs transurethral resection of the prostate (TURP) is presented as well as results of patients treated with a temperature sensing laser system. The ®rst study included 44 patients treated in a prospective randomised study (randomisation ILC vs TURP 2 : 1) comparing changes in objective and subjective parameters. In the second part of the study the outcome of the treatment of 34 patients with BPH using ILC performed with a temperature-sensing laser system are presented. The clinical outcome at 12, 26, 52 and 104 weeks was evaluated with symptom scores, quality of life measures, changes in voided volume, post void residual, and peak¯ow rate. In addition changes in prostate volume and urodynamic parameters at half a year follow-up are presented.
Introduction
In recent years, several techniques employing lasers have been introduced for the treatment of voiding complaints and bladder outlet obstruction due to benign prostatic hyperplasia (BPH). The initial results of prospective but non-randomised studies using interstitial laser coagulation (ILC) were encouraging; a signi®cant improvement of voiding parameters have been reported at minimal morbidity.
1 Most of these studies were done with neodymium: YAG lasers. 2 More recently, an interstitial diode laser system was introduced demonstrating promising initial clinical outcomers. 3 Thus far, however, no data has been available comparing ILC performed with this system to transurethral resection of the prostate (TURP). In this present study, long-term follow-up data are presented of a single centre, prospective randomised study of low power interstitial diode laser coagulation of the prostate vs TURP. We have also recently reported on the initial results using a diode laser system with temperature feedback. 4 Therefore we also report on long-term follow-up results using such a system.
Materials and methods
From October 1994 until April 1996, 44 consecutive patients were randomised to receive either ILC or TURP in a 2 : 1 ratio (14 TURP and 30 ILC) after giving informed consent. After termination of that study, a further 34 consecutive patients were treated in a phase II study, utilising the same device now equipped with a temperature sensing laser system. The objective of this phase II study was to investigate if objective improvement could be enhanced with temperature guided treatments. The documentation of this study was according to the same treatment protocol as for the randomised study. The major inclusion and exclusion criteria are shown in Table 1 . Preoperative investigations included history with the International Prostate Symptom Score (IPSS) with the corresponding quality of life index, and documentation of sexual function. The physical examination included digital rectal examination (DRE), blood chemistry included prostate speci®c antigen (PSA), and urine investigations included urine analysis and urine culture. Transrectal ultrasound of the prostate (TRUS) was performed (Combison 330 Voluson, Kretz Technik, Zipf, Austria) to measure the prostate volume and to determine its con®guration. In case of abnormality on either DRE, PSA-level or TRUS, ultrasound guided biopsies were performed. Urethrocystoscopy was carried out to judge the patency of the (prostatic) urethra and to exclude intravesical pathology. To document the voiding parameters, uro¯owmetry was performed (Urodyn 1000, Dantec, Skovlunde, Denmark) followed by the measurement of post void residual (PVR) with transabdominal ultrasound using a 3.5 MHz abdominal probe (Combison 330 Voluson, Kretz Technik, Zipf, Austria). To quantify the grade of bladder outlet obstruction, urodynamic investigation with pressure-¯ow (PQ) analysis was performed. Intravesical and rectal pressures were recorded using 8 Fr catheters mounted with micro-tip sensors (MTC, Dra È ger, Germany), and detrusor pressure was calculated as the difference between these. The digitally stored pressure and¯ow-data were analysed by a program developed at our department (UIC/BMC Research Center, Department of Urology, Nijmegen, the Netherlands).
The outcome was documented as the changes in these parameters as well as the morbidity encountered during and following the treatment at 3, 6, 12 and 24 months. Urodynamic studies were repeated at six months followup. Statistical analysis of the results was performed using the Independent Samples t-Test.
All procedures were performed by one of the authors utilising the video imaging technique only. The patients were hospitalized and discharged depending on the postoperative convalescence. Perioperative antibotic prophylaxis with cotrimoxazole-sulfatrim (960 mg twice daily for 7 d) was administered routinely.
Laser procedure
For ILC a diode laser system (Indigo 830, Indigo Medical, Palo Alto, USA) was used. The laser operates at a nominal 830 nm wavelength (range 800±850 nm). The laser energy is delivered via¯exible 600 micron quartz glass ®bre with a 1 cm long diffuser tip (diameter 1.8 mm) speci®cally designed for interstitial application (Figure 1a,b) .
Under general or spinal anaesthesia the patient was placed in the lithotomy position. Cystoscopy was performed using a 17 Fr compact cystoscope (Wolf, Knittlingen, Germany) and for the irrigation saline was used. Prior to laser application a 12 Fr suprapubic tube was inserted. Under direct visual guidance the laser ®bre was inserted up to its depth marker (Figure 2 ) into the adenomatous tissue at multiple locations into each lobe along the prostatic urethra from apex to base (Figure 3a± e). The mode of application and puncture protocol has been described extensively elsewhere. 3 In general the sites of ®bre placement were chosen to coagulate the bulk of hyperplastic tissue. Therefore the total number of ®bre placements varied depending on the size and con®gura-tion of the prostate. To prevent potential thermal damage to the dorsal capsule and adjacent structures the lateral lobes were always punctured in the lateral or ventrolateral direction and never in the dorsal direction. If a middle lobe was present it was treated with one or more punctures in the direction of the bladder in order to avoid subtrigonal placement.
In the randomised study patients were treated according to a lower energy protocol. Each individual ®bre placement received 1420 J in a standardised 4 min treatment cycle. Laser emission started at 10 W laser power and was gradually reduced during the treatment cycle to 5 W in order to achieve a rapid tissue heating and to maintain adequate intraprostatic temperatures. 3 In the non-randomised study the patients were treated using ILC with the Indigo 830e temperature sensing laser system. Energy was delivered at the power setting of 15 W during a three minute treatment cycle. As the optimal temperature for coagulation is estimated to be about 85 C the aim of the treatment was to reach and maintain this temperature at the site of treatment during the entire treatment cycle. A temperature-triggered feedback system was built into the laser unit so that during treatment the temperature was monitored continuously, and the temperature and power output formed a feedback loop that sought to maintain a temperature of 85 C. 4 Suprapubic catheters were removed when adequate voiding was demonstrated at scheduled follow-up visits (1, 2 or 4 weeks).
TURP procedure
Under general or spinal anaesthesia the patient was treated in the lithotomy position. For treatment a 24 Fr resectoscope (Stortz, Tuttlingen, Germany) was used in combination with glycine irrigation¯uid. The resection was performed according to standard procedure down to the capsule. The resected tissue was washed from the bladder, weighed and sent for pathological examination. The treatment was terminated when adequate haemostasis was achieved and followed by insertion of a 24 Fr indwelling transurethral catheter. Continuous irrigation was kept until haemostasis was complete. The catheter was removed according to the individual needs and the patient was dismissed if the clinical course was uneventful.
Results

Randomised study
Subjective outcome as measured by the IPS-Score demonstrated a signi®cant improvement in both the ILC and the TURP group. The results (average values and standard deviation) are highlighted in detail in Table 2a . The symptomatic improvements were 43% and 45% in the ILC group and 84% and 77% in the TURP group at 12 and 24 months, respectively. Further analysis showed no clinical factors predicting treatment outcomes in either group. Improvement in the quality of life index is shown in Table 2b . In the TURP group, preoperatively 89% stated to have normal erectile function, compared to 92% in the ILC group. At 12 months post treatment 3 patients (all three of them from the TURP group) mentioned changes of their erectile function. In 25% of the TURP patients and in 58% of the ILC patients con®rmed the maintenance of prograde ejaculation. The objective outcome as measured by changes in maximum¯owmetry demonstrated that TURP outperforms ILC when using the lower energy protocol. At 12 and 24 months follow up the improvement was 63% and 41% in the ILC and 176% and 116% in the TURP group respectively (Table 2c ). The post void residual also decreased signi®cantly in both groups with a more pronounced improvement for the TURP group. The resected weight of the TURP group averaged 22 g (range 7± 40 g). The prostate volume after six months, measured by ultrasound, decreased from 50 AE 16 ml to 28 AE 11 ml in the TURP group and from 46 AE 20 to 40 AE 21 ml in the ILC group.
In the ILC group we could demonstrate a trend between the number of ®bre placements and the volume reduction. However, the percentage of volume reduction was not correlated to the objective clinical outcome. No other predicting factors were found either.
In the early postoperative period irritative (voiding) complaints to some extent were reported by almost all patients in both groups. Signi®cant symptoms or persisting complaints for more than one week, were reported more frequently in the ILC group. Transient haematuria was present in all patients during the ®rst days after treatment, however more pronounced in the TURP group. In none of the patients of either group a clot retention occurred, and no patient needed a blood transfusion. Non-randomised phase II study
The outcome as assessed by objective and subjective parameters during the follow-up is also presented in Table 2 . The symptoms improved signi®cantly with a 70%, 65% and 67% decrease at 6, 12, and 24 months respectively. Compared to baseline values the maximum ow improved by 73% at 6 months, 94% at 12 months and 58% at 24 months, with the post void residual decreasing signi®cantly from 67 ml (s.d. AE 96 ml) to 20 ml (s.d. AE 48 ml), 51 ml (s.d. AE 79 ml) and 33 ml (s.d. AE 42 ml) at 6, 12 and 24 months respectively.
The laser treatment caused some morbidity; irritative voiding complaints occurred in most of the patients up to two to four weeks and transient haematuria was present in most patients during the ®rst days after treatment, but no patient needed a blood transfusion. A suprapubic Urodynamic results
The urodynamic results were measured by the Urethral Resistance Factor (URA) and obstruction grading according to the Scha È fer classes (Lin-PURR ) for the ILC group and the TURP group, respectively. After six months follow up the improvements in URA for the ILC group were 29% and 61% for the TURP group. When using the Lin-PURR classi®cation, the patients treated by ILC improved almost 1 Scha È fer class (3.6±2.7) whereas the TURP patients showed improved of more than 2 Scha È fer classes at an equal follow-up (Table 4) .
The results of the urodynamic investigation at screening did not predict the clinical outcome. However, when comparing the urodynamic results of the ILC group at week 26 a statistically signi®cant difference could be detected between those who would need adjuvant treatment (TURP) and those who were not in need for an additional treatment. The retreated group still remained obstructive (mean URA of 45 AE 10) vs unobstructed patients that need no further treatment (mean URA of 29 AE 13). For the Lin-PURR these values were 3.9 AE 0.9 versus 2.0 AE 1.4, respectively.
Non-randomised phase II study
In the group treated with the higher energy laser system the mean value of the URA was 46 cmH 2 O (s.d. AE 19 cmH 2 O) and that of Lin-PURR was 3.2 (s.d. AE 1.5) when measured at screening. The parameters were measured again at a follow-up of 26 weeks, and a signi®cant improvement could be seen in both: URA improved by 46% and Lin-PURR by 47% (Table 4) .
Discussion
Within the last few years, the overall ef®cacy of the various ways to perform laser treatment of BPH has been shown to be in the range of that of TURP, with a lower morbidity. 5 As a result of encouraging improvements in clinical results of initial studies employing laser technology, many urologists nowadays perform laser prostatectomy. To play a signi®cant role in the future management of symptomatic BPH, laser technology must be compared to TURP, and attention must be paid to the negative as well as the positive aspects of the results. When the results are evaluated, many urologists will mainly focus on the improvement in symptom score and the improvement in peak¯ow rate. These must, however, always be compared to TURP. In addition, the morbidity associated with the use of the laser must not be neglected; this must also be measured against the morbidity of TURP. Up to the present data, the number of prospective randomised studies comparing laser treatment to TURP presenting long term follow-up are limited. 6, 7 From the initial randomised study, comparing treatment results of a lower interstitial laser protocol to the treatment results of TURP, we have learned that clinical parameters of patients treated with ILC improved substantially from pretreatment to follow-up ( 3 ) within six months (approximately 13%). The improvements observed in patients treated by TURP outperformed those following ILC. In the ILC group the retreatment rate was signi®cant (21%). When identifying criteria for response, it appeared that non-responders were younger patients with a higher grade of bladder outlet obstruction. It is our experience that older patients accept their failure in responding to therapy more easily than their younger counterparts. The morbidity associated with laser therapy was signi®cantly less than following TURP. In the early postoperative period, severe complications were rare. Most patients experienced a transient worsening of urinary¯ow and obstructive symptoms and therefore a suprapubic catheter was left in place for an average of 27 d. Most of the patients suffered from irritating voiding complaints and uncomplicated urinary tract infections were seen in 34% of patients. Patients treated by laser respectively TURP were admitted for at average 2.3 and 3.8 d. Patients treated with TURP also often mentioned irritative symptoms during the immediate postoperative period, and urinary tract infection were con®rmed in four patients. In contrasts to the TURP group, however, the retreatment for persistent or recurrent symptomatic obstruction in the ILC group was considerably higher. Obviously the amount of ablated tissue resulting in relief of out¯ow obstruction and reduction of symptoms needs to be optimised, still preserving the advantages of the minimal invasive laser procedure. The upgraded treatment protocol indicated that an improvement of the outcome could be achieved using a temperature feed back system with a higher power setting while the treatment time could be reduced. As a result, the clinical outcome could indeed be improved resulting in a higher durability than that achieved following treatment according to the lower energy protocol.
Overall we may conclude that interstitial laser coagulation of the prostate has become more and more accepted as a therapeutic treatment option for patients with lower urinary tract symptoms due to BPH. However, several important items need to be clari®ed. First of all a durable and signi®cant improvement of subjective and objective parameters is an absolute condition. From this present study we have learned that the overall treatment results are encouraging and with the introduction of the higher energy modalities also ablative and more durable results could be achieved. This higher ef®cacy, however, is still associated with a considerable morbidity. Obviously, treatment at higher energy levels results in a higher tissue effect and thus higher ef®cacy, or in other words: the hotter, the better. And, vice versa, it seems that the better the outcome, the higher the morbidity. Indeed, an analogous trend is observed in patients treated with high energy thermotherapy of the prostate. 8 Moreover this suggests that patients who are treatment failures treatment were inadequately treated and most possibly would have done better if for example the number of sticks would have been higher. Yet, this can not be con®rmed within the present study. The ultimate acceptance of laser prostatectomy will indeed not only depend on short and long term outcome in comparison to standard treatment, but also on an improvement in treatment related morbidity. One of the key issues is the high incidence of post treatment retention. The introduction of temporary stents, however, has shed a new light on this problem. 9 Because the ef®cacy of heat treatments is closely related to an increase in thermal dose, post treatment oedema is a logical consequence that needs to be taken care of. Temporary prostatic stents are relatively new devices that can be applied successfully in combination with laser treatment of the prostate. Initial clinical data on these temporary prostatic stents appear to be very positive and might solve the problem of urinary retention after treatment with minimal morbidity. 10 
Conclusions
In summary, the initial enthusiasm for ILC in the management of symptomatic BPH has been maintained, although the initial achieved results have been criticised. Improvements in technology makes it an evolving technology. Nevertheless, the critical attitude must be maintained and, in addition, apart from future improvements of the technology itself, clinical evaluation must be looked at from the points of view of ef®cacy versus morbidity and durability. To determine the exact place of interstitial laser coagulation in the total treatment scala of BPH, further data on durability and retreatment rates are obligatory. However, there remains place for some degree of enthusiasm about the technology, and the encouraging results that have been presented will, hopefully, be sustained in even longer-term studies.
